432 filings
Page 5 of 22
SC 13G
EcoR1 Capital, LLC
3 Feb 22
GALAPAGOS / EcoR1 Capital ownership change
12:00am
6-K
GLPG
Galapagos NV
27 Jan 22
Galapagos appoints Paul Stoffels as Chief Executive Officer
12:00am
6-K
GLPG
Galapagos NV
26 Jan 22
Galapagos creates new subscription right plan
5:30pm
6-K
GLPG
Galapagos NV
19 Jan 22
Jyseleca®▼ (Filgotinib) Licensed for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis In Great Britain
11:37am
6-K
GLPG
Galapagos NV
13 Jan 22
Galapagos creates new subscription right plan
4:32pm
6-K
GLPG
Galapagos NV
10 Jan 22
Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
3:12pm
6-K
GLPG
Galapagos NV
6 Dec 21
Current report (foreign)
6:00am
6-K
GLPG
Galapagos NV
29 Nov 21
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
6:00am
6-K
GLPG
Galapagos NV
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
6-K
GLPG
Galapagos NV
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
SC 13D
Van Herk Investments B.V.
2 Nov 21
GALAPAGOS / VAN HERK INVESTMENTS B.V. ownership change
4:44pm
S-8
GLPG
Galapagos NV
26 Oct 21
Registration of securities for employees
4:07pm
6-K
GLPG
Galapagos NV
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
GLPG
Galapagos NV
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
GLPG
Galapagos NV
21 Sep 21
Current report (foreign)
12:00am
6-K
GLPG
Galapagos NV
20 Sep 21
Current report (foreign)
9:26am
6-K
GLPG
Galapagos NV
31 Aug 21
Galapagos announces planned retirement of CEO
3:46pm
6-K
GLPG
Galapagos NV
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
GLPG
Galapagos NV
14 Jul 21
Current report (foreign)
5:27pm
6-K
GLPG
Galapagos NV
14 Jul 21
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
5:13pm